Lullo JJ. JAAD Game Changers: "Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)". J Am Acad Dermatol 2026 Jun 3:S0190-9622(26)02816.
PMID: 42242375